Cempra’s Fusidic Acid Achieves Primary Endpoint in Phase 3 Study of ABSSSI
24 févr. 2017 07h00 HE
|
Cempra, Inc.
—Fusidic acid met primary endpoint and secondary efficacy endpoints— —Fusidic acid well tolerated in the study— CHAPEL HILL, N.C., Feb. 24, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a...
Cempra Appoints Dr. David Zaccardelli as Acting Chief Executive Officer, Promotes Chief Commercial Officer David Moore to President
12 déc. 2016 09h01 HE
|
Cempra, Inc.
—Leadership changes bolster manufacturing, regulatory and commercial expertise— —Cempra founder, president and CEO, Dr. Prabhavathi Fernandes, announces retirement from the company and...
Cempra Submits Marketing Authorization Application to EMA for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia
28 juin 2016 07h00 HE
|
Cempra, Inc.
CHAPEL HILL, N.C., June 28, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
FDA Grants Qualified Infectious Disease Product Designation to Taksta(TM) Cempra's Fusidic Acid Antibiotic
18 sept. 2015 07h00 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Sept. 18, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present at Two Upcoming Scientific Conferences
17 avr. 2015 07h30 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., April 17, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...